The US Food and Drug Administration (FDA) has approved Anacor Pharmaceuticals’ Eucrisa (crisaborole) ointment for the treatment of mild-to-moderate eczema (atopic dermatitis) in patients aged two and older.

Chronic inflammatory skin disease Atopic dermatitis is often referred to as ‘eczema' and is the most common of the many types, with onset typically occurring in childhood and possibly continuing through to adulthood.

FDA Center for Drug Evaluation and Research (CDER) Office of Drug Evaluation III deputy director Amy Egan said: "Today’s approval provides another treatment option for patients dealing with mild-to-moderate atopic dermatitis."

The disease is caused by a combination of genetic, immune and environmental factors. The skin develops red, scaly and crusted itchy bumps.

Scratching will lead to swelling, cracking, ‘weeping' clear fluid, and the skin will also become rough and thick.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"Today’s approval provides another treatment option for patients dealing with mild-to-moderate atopic dermatitis."

The safety and efficacy of the phosphodiesterase 4 (PDE-4) inhibitor Eucrisa ointment were established in two placebo-controlled trials.

A total of 1,522 participants aged two to 79 years with atopic dermatitis participated in the trials.

Serious side effects of Eucrisa include hypersensitivity reactions and most the common side effect is application site pain, including burning or stinging.

The ointment is not recommended for patients who have had a hypersensitivity reaction to its active ingredient, crisaborole.


Image: Dermatitis or eczema of the hands. Photo: courtesy of James Heilman, MD.